Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves’ orbitopathy: a case series

Alemtuzumab—a monoclonal antibody targeting the CD52 glycoprotein expressed by most mature leucocytes—effectively decreases relapse rate and disability progression in early, relapsing–remitting multiple sclerosis (MS). However, secondary autoimmune disorders complicate therapy in nearly 50% of treat...

Full description

Saved in:
Bibliographic Details
Published in:Eye (Lond)
Main Authors: Roos, Jonathan C. P., Moran, Carla, Chatterjee, V. Krishna, Jones, Joanne, Coles, Alasdair, Murthy, Rachna
Format: Artigo
Language:Inglês
Published: Nature Publishing Group UK 2018
Subjects:
Conference Proceeding
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6367353/
https://ncbi.nlm.nih.gov/pubmed/30498266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41433-018-0282-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items